Immunitas Therapeutics

We are committed to the growth and success of our employees. We are scientific explorers committed to fostering a culture of innovation at each step of the drug development process. We are advancing our wholly owned development candidate, IMT-009 (a-CD161 mAb), through clinical evaluation. We are committed to providing meaningful, goal-oriented internship and co-op programs to both undergraduate and graduate students. Immunitas is committed to discovering and developing novel, differentiated therapeutics for patients with cancer. Our discovery engine combines deep expertise in single-cell genomics with customized machine learning approaches to elucidate immune cell populations that are key actors in immuno-oncology. Through our fully integrated internal R&D capabilities and parallel discovery efforts, we are accelerating the timeline from discovery to the clinic. We believe that high-functioning teams thrive when facing scientific challenges, and as a result we place high value on team members who are both innovative and collaborative.